CM
DNTH icon

Crestline Management’s Dianthus Therapeutics DNTH Stock Holding History

Crestline Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,633
Closed -$31K – 228
2022
Q2 		$31K Sell
1,633
-21
-1% -$519 ﹤0.01% 220
2022
Q1 		$77K Buy
+1,654
New +$90.4K 0.01% 256

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management's DNTH Position: Q3 2022 in Review

Crestline Management sold out of Dianthus Therapeutics (DNTH) in Q3 2022, closing a stake of 1,633 shares — an estimated $31K sold.

Crestline Management first reported a position in DNTH in Q1 2022 and held it in 2 quarters. The position peaked at $77K in Q1 2022. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2022.

  • Crestline Management reported no remaining Dianthus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 1,633 Dianthus Therapeutics shares in Q3 2022, an estimated $31K.
  • Crestline Management first reported a position in Dianthus Therapeutics in Q1 2022 and held it in 2 quarters.
  • Crestline Management's Dianthus Therapeutics position peaked at $77K in Q1 2022.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.